In-vivo Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran) in Compared with The Reference Drug (Jentadueto® 2.5/1000 mg, Boehringer Ingelheim, Germany) in fasting condition in healthy volunteers
In-vivo Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma Co Tablets of The Test Drug in Compared with The Reference Drug (GLYXAMBI® Tab 25/5 mg. Beohringer Ingelheim Germany) In Healthy Volunteers
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg manufactured by Kharazmi Co.versus originator brand GLYXAMBI® 25/5 mg manufactured by ??Boehringer ????? Co in fasting condition in healthy volunteers
100 Clinical Results associated with Kharazmi Pharmaceutical Co.
0 Patents (Medical) associated with Kharazmi Pharmaceutical Co.
100 Deals associated with Kharazmi Pharmaceutical Co.
100 Translational Medicine associated with Kharazmi Pharmaceutical Co.